Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Dianthus Therapeutics Inc.

NASDAQ DNTH
$26.50 1.84 7.46%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 35 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
649.25M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
639.36M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
35.79M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
21.56 %

Upcoming events Dianthus Therapeutics Inc.

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Dianthus Therapeutics Inc.

Stock analysis Dianthus Therapeutics Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-6.45 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
2.06 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-7.65 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.12 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-30.65 -50.00

Price change Dianthus Therapeutics Inc. per year

14.86$ 29.90$
Min Max

Summary analysis Dianthus Therapeutics Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Dianthus Therapeutics Inc.

Revenue and net income Dianthus Therapeutics Inc.

All parameters

About company Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Address:
7 Times Square, New York, NY, United States, 10036
Company name: Dianthus Therapeutics Inc.
Issuer ticker: DNTH
ISIN: US2528281080
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2023-09-12
Sector: Healthcare
Industry: Biotechnology
Site: https://dianthustx.com